Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen.

Moholisa RR, Schomaker M, Kuhn L, Meredith S, Wiesner L, Coovadia A, Strehlau R, Martens L, Abrams EJ, Maartens G, McIlleron H.

Antivir Ther. 2014;19(4):399-406. doi: 10.3851/IMP2749. Epub 2014 Feb 12.

2.

High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting.

Puthanakit T, Jourdain G, Suntarattiwong P, Chokephaibulkit K, Siangphoe U, Suwanlerk T, Prasitsuebsai W, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Waranawat N, Ananworanich J; HIV-NAT 086 study team.

AIDS Res Ther. 2012 Jun 18;9(1):20. doi: 10.1186/1742-6405-9-20.

3.

Management of paediatric HIV-1 resistance.

Gupta RK, Gibb DM, Pillay D.

Curr Opin Infect Dis. 2009 Jun;22(3):256-63. Review.

4.

Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.

Robbins BL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrell C, Smith ME, Alvero C, Fenton T, Heckman B, Pelton SI, Aldrovandi G, Borkowsky W, Rodman J, Havens PL; PACTG 1038 Team.

Antimicrob Agents Chemother. 2008 Sep;52(9):3276-83. doi: 10.1128/AAC.00224-08. Epub 2008 Jul 14.

5.

Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.

Larru B, de Mendoza C, Bellón JM, de José MI, Mellado MJ, Soriano V, Muñoz-Fernandez MA, Ramos JT.

BMC Infect Dis. 2007 Jun 10;7:55.

Supplemental Content

Support Center